Clinical Research Directory

Inclusion Criteria: * Age 18 years or older. * Female patient with stage II and III triple-negative breast cancer, requiring neoadjuvant chemo-immunotherapy according to the KEYNOTE-522 regimen or any neoadjuvant treatment including chemotherapy and immunotherapy validated in standard care or a clinical trial, regardless of the treatment regimen (ER \< 10%, PR \< 10%, HER2 0, and HER2 low). * Patient requiring the placement of a localization clip as part of their standard clinical care management. * Patient who has read the information sheet and signed the informed consent. * Patient affiliated with a Social Security health insurance scheme. Exclusion Criteria: * Metastatic breast cancer documented by staging workup (PET scan or thoraco-abdomino-pelvic CT scan + bone scan). * Patient who has undergone primary surgery. * INR \< 1.5; Platelets \< 50,000/$\\mu$L. * Patient presenting with multiple primary malignant tumors. * Patient with HIV infection, Hepatitis C, or active Hepatitis B. * Patient taking: * Dual antiplatelet therapy: Acetylsalicylic acid + Clopidogrel without the possibility of suspending Clopidogrel for 5 days, * Ticagrelor without the possibility of suspension for 5 days, * Prasugrel without the possibility of suspension for 7 days, * Vitamin K antagonists (acenocoumarol, warfarin, or fluindione) with INR \< 2 or \> 3, without the possibility of suspension.